Newton, MA, United States of America

Deborah Molrine

This inventor holds 5 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: University of Massachusetts, Medarex Inc., E. R. Squibb Sons, Inc.. Active years: 2009-2015.

USPTO Granted Patents = 5 

% Patents Active = 100.0


 

Average Co-Inventor Count = 10.0

ph-index = 3

Forward Citations = 57(Granted Patents)


Company Filing History:


Years Active: 2009-2015

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Deborah Molrine

Introduction

Deborah Molrine is a prominent inventor based in Newton, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting clostridium difficile toxins. With a total of 5 patents to her name, her work has had a substantial impact on medical research and treatment options.

Latest Patents

Among her latest patents, Deborah has developed antibodies that specifically bind to toxins of clostridium difficile. These patents detail the methods of making and using these antibodies and their antigen binding portions. This innovative work is crucial in addressing infections caused by this harmful bacterium.

Career Highlights

Deborah has worked with notable organizations such as the University of Massachusetts and Medarex Inc. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Donna Ambrosino and Gregory Babcock. Their collaborative efforts have further advanced the research and development of therapeutic solutions in biotechnology.

Conclusion

Deborah Molrine's contributions to the field of biotechnology through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to influence the development of effective treatments for serious medical conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…